CoChat
Sign Up
Cited by 39Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

Longitudinal validity of PET‐based staging of regional amyloid deposition

Open access
Jelistratova, Irina, Teipel, Stefan J., Grothe, Michel J.·2020·Human Brain Mapping
DOI 10.1002/hbm.25121PMC PMC7502828
Open this paper in CoChat — free account

Abstract

Positron emission tomography (PET)-based staging of regional amyloid deposition has recently emerged as a promising tool for sensitive detection and stratification of pathology progression in Alzheimer's Disease (AD). Here we present an updated methodological framework for PET-based amyloid staging using region-specific amyloid-positivity thresholds and assess its longitudinal validity using serial PET acquisitions. We defined region-specific thresholds of amyloid-positivity based on Florbetapir-PET data of 13 young healthy individuals (age ≤ 45y), applied these thresholds to Florbetapir-PET data of 179 cognitively normal older individuals to estimate a regional amyloid staging model, and tested this model in a larger sample of patients with mild cognitive impairment (N = 403) and AD dementia (N = 85). 2-year follow-up Florbetapir-PET scans from a subset of this sample (N = 436) were used to assess the longitudinal validity of the cross-sectional model based on individual stage transitions and data-driven longitudinal trajectory modeling. Results show a remarkable congruence between cross-sectionally estimated and longitudinally modeled trajectories of amyloid accumulation, beginning in anterior temporal areas, followed by frontal and medial parietal areas, the remaining associative neocortex, and finally primary sensory-motor areas and subcortical regions. Over 98% of individual amyloid deposition profiles and longitudinal stage transitions adhered to this staging scheme of regional pathology progression, which was further supported by corresponding changes in cerebrospinal fluid biomarkers. In conclusion, we provide a methodological refinement and longitudinal validation of PET-based staging of regional amyloid accumulation, which may help improving early detection and in-vivo stratification of pathologic disease progression in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hbm.25121

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Serial amyloid PET scans show Aβ deposition starts in anterior temporal areas and spreads to frontal and medial parietal areas, associative neocortex, and later primary sensorimotor areas and subcortical regions, mirroring neuropathological staging of AD.

    “Serial amyloid PET scans show that Αβ deposition starts in the anterior temporal areas and spreads to the frontal and medial parietal areas, the associative neocortex and later on at the primary sensorimotor areas and subcortical regions mirroring the neuropathological staging of AD pathology [164–166].”

    From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [165]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 46

  1. Ashburner, J. (2007). A fast diffeomorphic image registration algorithm. NeuroImage, 38(1), 95– 113. 10.1016/j.neuroimage.2007.07.007 17761438 · DOI · Paper page
  2. Beach, T. G., Maarouf, C. L., Intorcia, A., Sue, L. I., Serrano, G. E., Lu, M., … Roher, A. E. (2018). Antemortem‐Postmortem correlation of Florbetapir (18F) PET amyloid imaging with quantitative biochemical measures of Aβ42 but not Aβ40. Journal of Alzheimer's Disease: JAD, 61(4), 1509– 1516. 10.3233/JAD-170762 29376867 · DOI
  3. Bilgel, M., Prince, J. L., Wong, D. F., Resnick, S. M., & Jedynak, B. M. (2016). A multivariate nonlinear mixed effects model for longitudinal image analysis: Application to amyloid imaging. NeuroImage, 134, 658– 670. 10.1016/j.neuroimage.2016.04.001 27095307 PMC4912927 · DOI
  4. Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011). Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. Journal of Neuropathology and Experimental Neurology, 70(11), 960– 969. 10.1097/NEN.0b013e318232a379 22002422 · DOI · Paper page
  5. Brendel, M., Högenauer, M., Delker, A., Sauerbeck, J., Bartenstein, P., Seibyl, J., … Alzheimer's Disease Neuroimaging Initiative. (2015). Improved longitudinal [(18)F]‐AV45 amyloid PET by white matter reference and VOI‐based partial volume effect correction. NeuroImage, 108, 450– 459. 10.1016/j.neuroimage.2014.11.055 25482269 · DOI
  6. Cho, S. H., Shin, J.‐H., Jang, H., Park, S., Kim, H. J., Kim, S. E., … Alzheimer's Disease Neuroimaging Initiative. (2018). Amyloid involvement in subcortical regions predicts cognitive decline. European Journal of Nuclear Medicine and Molecular Imaging, 45(13), 2368– 2376. 10.1007/s00259-018-4081-5 29980831 PMC6439472 · DOI
  7. Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., … AV‐45‐A16 Study Group. (2012). Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid‐β plaques: A prospective cohort study. Lancet Neurology, 11(8), 669– 678. 10.1016/S1474-4422(12)70142-4 22749065 · DOI · Paper page
  8. Farrell, M. E., Chen, X., Rundle, M. M., Chan, M. Y., Wig, G. S., & Park, D. C. (2018). Regional amyloid accumulation and cognitive decline in initially amyloid‐negative adults. Neurology, 91(19), e1809– e1821. 10.1212/WNL.0000000000006469 30305451 PMC6251600 · DOI
  9. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini‐mental state”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189– 198. 10.1016/0022-3956(75)90026-6 1202204 · DOI · Paper page
  10. Gonneaud, J., Arenaza‐Urquijo, E. M., Mézenge, F., Landeau, B., Gaubert, M., Bejanin, A., … Chételat, G. (2017). Increased florbetapir binding in the temporal neocortex from age 20 to 60 years. Neurology, 89(24), 2438– 2446. 10.1212/WNL.0000000000004733 29150540 · DOI
  11. Gonzalez‐Escamilla, G., Lange, C., Teipel, S., Buchert, R., Grothe, M. J., & Initiative, A.'s. D. N. (2017). PETPVE12: An SPM toolbox for partial volume effects correction in brain PET ‐ application to amyloid imaging with AV45‐PET. NeuroImage, 147, 669– 677. 10.1016/j.neuroimage.2016.12.077 28039094 · DOI
  12. Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., & Alzheimer's Disease Neuroimaging Initiative. (2017). In vivo staging of regional amyloid deposition. Neurology, 89(20), 2031– 2038. 10.1212/WNL.0000000000004643 29046362 PMC5711511 · DOI · Paper page
  13. Hanseeuw, B. J., Betensky, R. A., Mormino, E. C., Schultz, A. P., Sepulcre, J., Becker, J. A., … Harvard Aging Brain Study. (2018). PET staging of amyloidosis using striatum. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 14(10), 1281– 1292. 10.1016/j.jalz.2018.04.011 PMC6219621 29792874 · DOI
  14. Jack, C. R., Jr., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., … Petersen, R. C. (2017). Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 13(3), 205– 216. 10.1016/j.jalz.2016.08.005 PMC5344738 27697430 · DOI · Paper page
  15. Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., … Trojanowski, J. Q. (2013). Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. The Lancet Neurology, 12, 207– 216. 10.1016/s1474-4422(12)70291-0 23332364 PMC3622225 · DOI · Paper page
  16. Josephs, K. A., Murray, M. E., Whitwell, J. L., Tosakulwong, N., Weigand, S. D., Petrucelli, L., … Dickson, D. W. (2016). Updated TDP‐43 in Alzheimer's disease staging scheme. Acta Neuropathologica, 131(4), 571– 585. 10.1007/s00401-016-1537-1 26810071 PMC5946692 · DOI
  17. Joshi, A. D., Pontecorvo, M. J., Clark, C. M., Carpenter, A. P., Jennings, D. L., Sadowsky, C. H., … Florbetapir F 18 Study Investigators. (2012). Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 53(3), 378– 384. 10.2967/jnumed.111.090340 22331215 · DOI
  18. Landau, S. M., Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., … Jagust, W. J. (2015). Measurement of longitudinal β‐amyloid change with 18F‐florbetapir PET and standardized uptake value ratios. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 56(4), 567– 574. 10.2967/jnumed.114.148981 PMC5313473 25745095 · DOI · Paper page
  19. Landau, S. M., Horng, A., Jagust, W. J., & Alzheimer's Disease Neuroimaging Initiative. (2018). Memory decline accompanies subthreshold amyloid accumulation. Neurology, 90(17), e1452– e1460. 10.1212/WNL.0000000000005354 29572282 PMC5921038 · DOI
  20. Landau, S. M., Thomas, B. A., Thurfjell, L., Schmidt, M., Margolin, R., Mintun, M., … Alzheimer's Disease Neuroimaging Initiative. (2014). Amyloid PET imaging in Alzheimer's disease: A comparison of three radiotracers. European Journal of Nuclear Medicine and Molecular Imaging, 41(7), 1398– 1407. 10.1007/s00259-014-2753-3 24647577 PMC4055504 · DOI
  21. Marinescu, R. V., Eshaghi, A., Lorenzi, M., Young, A. L., Oxtoby, N. P., Garbarino, S., … Alexander, D. C. (2019). DIVE: A spatiotemporal progression model of brain pathology in neurodegenerative disorders. NeuroImage, 192, 166– 177. 10.1016/j.neuroimage.2019.02.053 30844504 · DOI
  22. Matsubara, K., Ibaraki, M., Shimada, H., Ikoma, Y., Suhara, T., Kinoshita, T., & Ito, H. (2016). Impact of spillover from white matter by partial volume effect on quantification of amyloid deposition with [11C]PiB PET. NeuroImage, 143, 316– 324. 10.1016/j.neuroimage.2016.09.028 27639351 · DOI
  23. Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019). Staging β‐amyloid pathology with amyloid positron emission tomography. JAMA Neurology, 76, 1319 10.1001/jamaneurol.2019.2214 PMC6646987 31314895 · DOI · Paper page
  24. Müller‐Gärtner, H. W., Links, J. M., Prince, J. L., Bryan, R. N., McVeigh, E., Leal, J. P., … Frost, J. J. (1992). Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI‐based correction for partial volume effects. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 12(4), 571– 583. 10.1038/jcbfm.1992.81 1618936 · DOI
  25. Navitsky, M., Joshi, A. D., Kennedy, I., Klunk, W. E., Rowe, C. C., Wong, D. F., … Devous, M. D., Sr. (2018a). Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 14(12), 1565– 1571. 10.1016/j.jalz.2018.06.1353 30006100 · DOI · Paper page
  26. Ni, R., Gillberg, P.‐G., Bergfors, A., Marutle, A., & Nordberg, A. (2013). Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. Brain: A Journal of Neurology, 136(Pt 7), 2217– 2227. 10.1093/brain/awt142 23757761 · DOI
  27. Ottoy, J., Verhaeghe, J., Niemantsverdriet, E., Wyffels, L., Somers, C., De Roeck, E., … Staelens, S. (2017). Validation of the Semiquantitative static SUVR method for 18F‐AV45 PET by pharmacokinetic Modeling with an arterial input function. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 58(9), 1483– 1489. 10.2967/jnumed.116.184481 28336779 · DOI
  28. Palmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., … Hansson, O. (2017). Earliest accumulation of β‐amyloid occurs within the default‐mode network and concurrently affects brain connectivity. Nature Communications, 8(1), 1214 10.1038/s41467-017-01150-x PMC5663717 29089479 · DOI · Paper page
  29. Reitan, R. M. (1958). Validity of the trail making test as an indicator of organic brain damage. Perceptual and Motor Skills, 8(3), 271– 276. 10.2466/pms.1958.8.3.271 · DOI
  30. Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Sr., Rieck, J. R., Hebrank, A. C., Diaz‐Arrastia, R., … Park, D. C. (2012). β‐Amyloid burden in healthy aging: Regional distribution and cognitive consequences. Neurology, 78(6), 387– 395. 10.1212/WNL.0b013e318245d295 22302550 PMC3280058 · DOI · Paper page
  31. Rullmann, M., Dukart, J., Hoffmann, K.‐T., Luthardt, J., Tiepolt, S., Patt, M., … Barthel, H. (2016). Partial‐volume effect correction improves quantitative analysis of 18F‐Florbetaben β‐amyloid PET scans. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 57(2), 198– 203. 10.2967/jnumed.115.161893 26541776 · DOI
  32. Sabri, O., Seibyl, J., Rowe, C., & Barthel, H. (2015). Beta‐amyloid imaging with florbetaben. Clinical and Translational Imaging, 3(1), 13– 26. 10.1007/s40336-015-0102-6 25741488 PMC4339690 · DOI
  33. Sakr, F. A., Grothe, M. J., Cavedo, E., Jelistratova, I., Habert, M.‐O., Dyrba, M., … Alzheimer Precision Medicine Initiative (APMI). (2019). Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT‐preAD study. Alzheimer's Research & Therapy, 11(1), 15 10.1186/s13195-019-0466-3 PMC6357385 30704537 · DOI
  34. Schmidt, M. E., Chiao, P., Klein, G., Matthews, D., Thurfjell, L., Cole, P. E., … Alzheimer's Disease Neuroimaging Initiative. (2015). The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 11(9), 1050– 1068. 10.1016/j.jalz.2014.09.004 25457431 · DOI
  35. Schoenberg, M. R., Dawson, K. A., Duff, K., Patton, D., Scott, J. G., & Adams, R. L. (2006). Test performance and classification statistics for the Rey auditory verbal learning test in selected clinical samples. Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists, 21(7), 693– 703. 10.1016/j.acn.2006.06.010 16987634 · DOI
  36. Seo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., … Rabinovici, G. D. (2017). Regional correlations between [11C]PIB PET and post‐mortem burden of amyloid‐beta pathology in a diverse neuropathological cohort. NeuroImage. Clinical, 13, 130– 137. 10.1016/j.nicl.2016.11.008 27981028 PMC5144753 · DOI · Paper page
  37. Sojkova, J., Goh, J., Bilgel, M., Landman, B., Yang, X., Zhou, Y., … Resnick, S. M. (2015). Voxelwise relationships between distribution volume ratio and cerebral blood flow: Implications for analysis of β‐amyloid images. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 56(7), 1042– 1047. 10.2967/jnumed.114.151480 PMC5367770 25977462 · DOI
  38. Sperling, R., Mormino, E., & Johnson, K. (2014). The evolution of preclinical Alzheimer's disease: Implications for prevention trials. Neuron, 84(3), 608– 622. 10.1016/j.neuron.2014.10.038 25442939 PMC4285623 · DOI · Paper page
  39. Su, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph‐Mathurin, N., … Dominantly Inherited Alzheimer Network. (2016). Quantitative amyloid imaging in autosomal dominant Alzheimer's disease: Results from the DIAN study group. PLoS One, 11(3), e0152082 10.1371/journal.pone.0152082 27010959 PMC4807073 · DOI · Paper page
  40. Teipel, S. J., Dyrba, M., Chiesa, P. A., Sakr, F., Jelistratova, I., Lista, S., … Grothe, M. J. (2020). In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. Neurobiology of Aging, 93, 98– 108. 10.1016/j.neurobiolaging.2020.03.011 32291113 · DOI
  41. Thal, D. R., Beach, T. G., Zanette, M., Lilja, J., Heurling, K., Chakrabarty, A., … Smith, A. P. L. (2018). Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β‐protein deposition. Acta Neuropathologica, 136(4), 557– 567. 10.1007/s00401-018-1897-9 30123935 PMC6132944 · DOI
  42. Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002). Phases of a beta‐deposition in the human brain and its relevance for the development of AD. Neurology, 58(12), 1791– 1800. Retrieved from. https://www.ncbi.nlm.nih.gov/pubmed/12084879 12084879
  43. Villain, N., Chételat, G., Grassiot, B., Bourgeat, P., Jones, G., Ellis, K. A., … Villemagne, V. L. (2012). Regional dynamics of amyloid‐β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: A voxelwise PiB‐PET longitudinal study. Brain, 135(Pt 7), 2126– 2139. 10.1093/brain/aws125 22628162 · DOI · Paper page
  44. Villemagne, V. L., Ong, K., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G., … Rowe, C. C. (2011). Amyloid imaging with (18)F‐florbetaben in Alzheimer disease and other dementias. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 52(8), 1210– 1217. 10.2967/jnumed.111.089730 21764791 · DOI
  45. Villeneuve, S., Rabinovici, G. D., Cohn‐Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., … Jagust, W. (2015). Existing Pittsburgh compound‐B positron emission tomography thresholds are too high: Statistical and pathological evaluation. Brain: A Journal of Neurology, 138(Pt 7, 2020– 2033. 10.1093/brain/awv112 25953778 PMC4806716 · DOI · Paper page
  46. Wang, H., & Song, M. (2011). Ckmeans.1d.Dp: Optimal k‐means clustering in one dimension by dynamic programming. The R Journal, 3(2), 29– 33. 27942416 PMC5148156

Cited by

Sorted by citations

Authors
Jelistratova, I., Teipel, S. J., & Grothe, M. J.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • Consejo Superior de Investigaciones Científicas (ES)
Corresponding author
Grothe, Michel J.
ORCID
Venue
Human Brain Mapping
Publisher
Wiley
Published
2020-07-10
Volume
41
Issue
15
Pages
4219-4231
ISSN
  • 1065-9471 (ISSN-L)
  • 1097-0193
DOI
10.1002/hbm.25121
PMC
PMC7502828
OpenAlex
W3042198414
Cited by
39
References
7
Citations by year
2026: 1 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 6 · 2021: 13 · 2020: 1
FWCI
4.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Human Brain Mapping (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
  • DZNE Pub (submittedVersion, other-oa)
Funders
  • Alzheimer Forschung Initiative (16037)
  • Instituto de Salud Carlos III (Miguel Servet contract [CP19/00031])
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
Alzheimer's disease, longitudinal validity, florbetapir, mild cognitive impairment, cerebrospinal fluid biomarkers, anterior temporal lobe
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Cerebral Cortex, Cross-Sectional Studies, Ethylene Glycols, Female, Humans, Longitudinal Studies, Male, Middle Aged, Reproducibility of Results, Biomarkers, Amyloid beta-Peptides, Disease Progression, Positron-Emission Tomography, Neuroimaging, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review